Detalles de la búsqueda
1.
Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).
Ann Surg Oncol
; 24(9): 2539-2546, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28447218
2.
Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.
Ann Surg Oncol
; 24(3): 669-675, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-27770345
3.
Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy.
Ann Surg Oncol
; 23(5): 1522-9, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-26714960
4.
Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).
Ann Surg Oncol
; 21(10): 3261-7, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25099655
5.
Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancer.
Surg Oncol
; 45: 101885, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36436423
6.
Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy.
JCO Precis Oncol
; 6: e2200197, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-36108259
7.
Breast cancer surgery trend changes since the introduction of BRCA1/2 mutation screening: a retrospective cohort analysis of 158 mutation carriers treated at a single institution.
Ann Surg Oncol
; 18(3): 745-51, 2011 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-20972632
Resultados
1 -
7
de 7
1
Próxima >
>>